Merck, Schering-Plough End Vytorin Investigation

Law360, New York (July 15, 2009, 12:00 AM EDT) -- In a settlement, Merck & Co. and Schering-Plough Corp. have agreed to reimburse 35 states and the District of Columbia for the costs associated with investigating a delay in the companies' release of negative results of a clinical trial of the jointly marketed cholesterol treatment Vytorin.

The deal announced Wednesday by the states and the companies also calls for Merck and Schering-Plough to obtain preapproval from the U.S. Food and Drug Administration for all direct-to-consumer television advertisements and to comply with FDA suggestions to modify drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.